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A B S T R A C T
Purpose: To use a physiologically based pharmacokinetic (PBPK) modelling system to predict the serum
levels achieved by two different intravenous loading doses of phenytoin.
Methods: A phenytoin pharmacokinetic model was used in the SimcypTM population-based ADME
simulator, simulating 100 children age 2–10 years receiving intravenous phenytoin (18 and 20 mg/kg).
Visual checks were used to evaluate the predictive performance of the candidate model.
Results: Loading with doses of 18 mg/kg, blood levels were sub-therapeutic in 22/100 (concentration at
2 h post infusion (C2h) <10 mg/mL), therapeutic in 62/100 (C2h 10–20 mg/mL), and supra-therapeutic in
16/100 (C2h > 20 mg/mL). Loading with 20 mg/kg, the percentages were 15, 59, and 26, respectively.
Increasing from 18 to 20 mg/kg increased the mean C2h from 16.0 to 17.9 mg/mL, and the mean AUC from
145 to 162 mg/mL/h. A C2h > 30 mg/mL was predicted in 4% and 8% of children in the 18 and 20 mg/kg
doses, with 3% predicted to have a C2h > 40 mg/mL following either dose. For maintenance doses, a 1st
dose of 2.5 or 5 mg/kg (intravenous) given at 12 h (after either 18 or 20 mg/kg loading) gives the highest
percentages of 10–20 mg/mL serum concentrations. For sub-therapeutic concentrations following
intravenous loading (20 mg/kg), a 1st maintenance dose (intravenous) of 10 mg/kg will achieve
therapeutic concentrations in 93%.
Conclusion: Use of PBPK modelling suggests that children receiving the 20 mg/kg intravenous loading dose
are at slightly increased risk of supra-therapeutic blood levels. Ideally, therapeutic drug monitoring is
required to monitor serum concentrations, although the dose regime suggested by the BNFc appear
appropriate.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The recommended intravenous loading dose of phenytoin in the
treatment of paediatric convulsive status epilepticus (CSE) in the
UK was increased from 18 to 20 mg/kg in January 2011, to reduce
the theoretical risk of miscalculation [1]. Phenytoin has a narrow
therapeutic range (10–20 mg/mL) and non-linear pharmacokinet-
ics [2], such that at high concentrations phenytoin exhibits zero
order kinetics in man (linear increase and decrease in serum
concentrations at higher dosages secondary to saturation of
metabolising enzymes). Consequently, toxic levels may take* Corresponding author at: University of Liverpool, Alder Hey Children’s Hospital,
Eaton Road, Liverpool L12 2AP, UK. Tel.: +44 1512284811.
E-mail address: D.hawcutt@liv.ac.uk (D.B. Hawcutt).
http://dx.doi.org/10.1016/j.seizure.2015.10.006
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights relonger to clear than most other drugs which exhibit ﬁrst-order
kinetics at all concentrations [3].
Subsequent analysis of phenytoin levels taken in routine clinical
practice has shown that the 20 mg/kg loading results in a similar
percentage of supra-therapeutic serum concentrations compared
with 18 mg/kg, but with a higher observed rate of clinical toxicity
[4]. At their most severe, phenytoin toxicity can include potentially
fatal cardiac arrhythmias, hypotension and neurological side effects
and particularly at higher serum concentrations [5].
Phenytoin metabolism is affected by concomitant medication
by a number of factors including obesity, concomitant medica-
tions, and pharmacogenomic variation in CYP2C9 and CYP2C19
[6–9], and signiﬁcant inter-individual variability in the pharma-
cokinetics has been noted in children [10].
The SimCYP population-based ADME simulator software allows
mechanistic-modelling and simulation of the processes involved inserved.
Fig. 1. Simulated mean (solid line) and 95% conﬁdence intervals (dashed line) of
phenytoin systemic concentration vs. time in 100 virtual children aged 2–10 years
at doses of 18 mg/kg (red) and 20 mg/kg (green) (For interpretation of the color
information in this ﬁgure legend, the reader is referred to the web version of the
article.).
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feature of this simulation software is its ability to provide not just
outputs based on an ‘individual’ but also outputs from individuals
within a population [11]. This has been used in paediatric
populations to successfully model the pharmacokinetics of
numerous medications [12,13].
The SimCYP software was used to model the outcomes of both
the 18 and 20 mg/kg intravenous loading doses of phenytoin. This
included an evaluation of the likelihood of supra- (>20 mg/mL) and
sub- (<10 mg/mL) therapeutic levels associated with the two doses
and an attempt to determine the optimal timing of additional
treatment with phenytoin (if required clinically). Current clinical
practice in our institution is to measure the total serum phenytoin
concentrations between 1 and 3 h following completion of the
infusion of the intravenous loading dose. The modelling mimicked
this practice and concentration values at 2 h post-loading dose are
reported as a representative value.
2. Methods
2.1. SimCYP model inputs
Apreviouslyreportedphenytoinpharmacokineticmodelwasused
in the SimCYPTM population-based ADME simulator (V14; SimCYP
Limited, Shefﬁeld, UK) [14]. The applicability of this model to use in
children was assessed by comparison to clinical data from children as
reported by the authors previously [4,15]. Hawcutt et al. [15] reported
on pharmacokinetic data following intravenous phenytoin adminis-
tered as an 18 mg/kg loading dose in children and a subsequent report
was provided by Piper et al. [4] following dosing at 20 mg/kg.
These papers reported phenytoin concentrations at time-points of
60–180 min post administration of phenytoin and calculated
the percentage that were within the therapeutic reference range
(10–20 mg/mL) sub-therapeutic (<10 mg/mL) and supra-therapeutic
(<20 mg/mL). A simulated trial to replicate the dosing reported by
these studies was created within the software. Visual checks were
used to evaluate the predictive performance of this model.
The simulation was performed in a population of 100
individuals aged from 2 to 10 years.
This model was interrogated to determine:
 What proportion of children achieved therapeutic concentra-
tions (C2h at 2 h post infusion) of phenytoin (10–20 mg/mL) when
given either 18 or 20 mg/kg loading dose?
 What is the population mean C2h concentration at 2 h for each
dose?
 What is the population mean ‘Area Under the Curve’ (AUC [0–
12 h]) for each dose?
 What proportion of children will have a C2h at 2 h post dose
>30 mg/mL or C2h > 40 mg/mL?
 When is the optimal time to administer the ﬁrst maintenance
dose following completion of the initial loading dose (20 mg/kg)
to avoid drug accumulation and supra-therapeutic concentra-
tions with potential clinical toxicity?
 Can these data assist with clinical decisions regarding intrave-
nous maintenance dosing in children with sub-therapeutic levels
of phenytoin?
3. Results
3.1. Loading doses
The simulated pharmacokinetic proﬁles of intravenous phe-
nytoin loading doses for 100 individuals aged from 2 to 10 yearswere created at doses of both 18 and 20 mg/kg. The mean
concentrations together with the 95% conﬁdence intervals are
shown in Fig. 1.
The concentration of the medication 2 h post-infusion (C2h) was
simulated in the population. The 18 mg/kg dose resulted in 62% of
the population achieving the therapeutic reference range (10–
20 mg/mL); 16% of the population achieved plasma concentrations
>20 mg/mL; and 22% did not achieve the 10 mg/mL level. The
20 mg/kg dose resulted in 59% of population achieving the
therapeutic reference range; 26% of the population achieved
plasma concentrations >20 mg/mL; and 15% did not achieve the
10 mg/mL level. Overall, an increase in dose from 18 to 20 mg/kg
increases the mean C2h from 16.0 to 17.9 mg/mL (Fig. 2A).
Limited pharmacokinetic data following intravenous phenytoin
in children administered as a 18 mg/kg loading dose infused over
20 min has been reported previously [15].
The modelled pharmacokinetics of phenytoin matched favour-
ably to the clinical data dosed at 18 mg/kg reported by Hawcutt
et al. [15]; the average C2h value was 16.0 mg/mL for the modelled
data and the mean Cmax value reported from the clinical data was
15.3 mg/mL. Seventy seven per cent of phenytoin concentration
levels were within the therapeutic reference range in the patient
population compared to 62% in the model; 3% of patients were sub-
therapeutic (22% in the model) and 19% of patients were supra-
therapeutic (16% in the model) [15]. The main difference between
the model and the reported clinical data was the number of sub-
therapeutic values observed at 2 h.
A comparison of the model and the clinical data reported at
20 mg/kg [4] showed a similar trend; 79% of phenytoin concen-
tration values in the patient population were within the
therapeutic reference range (59% modelled population); 0%
patients were sub-therapeutic (15% modelled) and 21% patients
were supra-therapeutic (26% modelled) [4]. The model showed an
increase in the percentage of supra-therapeutic plasma concen-
trations similar to that reported in the clinical data. However there
were many more sub-therapeutic levels observed in the modelled
data.
Comparison of the AUC values, minimum, 5th centile, mean,
95th centile and maximum values for each population is shown in
Fig. 2B. The increase in dose increases the AUC value for the ﬁrst
12 h following the infusion from 145 to 162 mg/mL/h.
An evaluation was undertaken of those children that had very
high blood level at both doses. Using the modelled 18 mg/kg
Fig. 2. (A) The concentration of phenytoin at 2 h (C2 h) post infusion at doses of 18 and 20 mg/kg. (B) The AUC of phenytoin at 0–12 h post infusion at doses of 18 and 20 mg/kg.
Both: Data show mean values, 95% conﬁdence intervals and minimum and maximum values recorded within the simulation.
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mL; 3% had levels greater than 40 mg/mL. Using the modelled
20 mg/kg dose level 8% had dose levels greater than 30 mg/mL; 3%
had levels greater than 40 mg/mL.
3.2. Maintenance doses
The effects of the time of the administration of the ﬁrst
maintenance dose were evaluated for 18 and 20 mg/kg loading
doses. A second simulation was run to include a subsequent
intravenous maintenance dose given at 12 h following the loading
dose (18 or 20 mg/kg). The mean proﬁles are shown in Fig. 3.
The percentage of individuals within the second simulation in
whom the next Cmax (concentration immediately following the
ﬁrst maintenance dose) were lower, within, or higher than the
therapeutic reference range is reported in Table 1 for a range of
maintenance doses. The maintenance doses which produces the
greatest of the simulated population whose second Cmax value is
within the target therapeutic reference range of 10–20 mg/mL
when administered 12 h following the loading dose is 5 mg/kg
(following an 18 mg/kg loading dose) and 2.5 mg/kg (following a
20 mg/kg loading dose) (Table 1).
Further interrogation of the data was undertaken in the
subgroup of the population in which the initial phenytoinFig. 3. Mean plasma concentration of phenytoin dosed as 18 mg/kg (red line) or
20 mg/kg (green line) followed by a maintenance dose of 5 mg/kg given at 12 h (For
interpretation of the color information in this ﬁgure legend, the reader is referred to
the web version of the article.).concentration was less than 10 mg/mL at 2 h after the loading
dose. Predictably, the proportion in which the levels were less than
10 mg/mL at 12 h following a maintenance dose decreased as the
maintenance dose increased, and the model was able to quantify
the proportions at, above or below the therapeutic reference range
for a range of maintenance doses. At 18 mg/kg, 22 subjects had
plasma levels of less than 10 mg/mL at 2 h; of these 21 (95%) were
below 10 mg/mL at 12 h following a 2.5 mg/kg maintenance dose;
17 (77%) with a maintenance dose of 5 mg/kg; 11 (50%) with a
maintenance dose of 7.5 mg/kg and 6 (28%) with a maintenance
dose of 10 mg/kg. At 20 mg/kg, 15 subjects had plasma levels less
than 10 mg/mL at 2 h; of these all 15 (100%) were below 10 mg/mL
at 12 h following a 2.5 mg/kg maintenance dose; 14 (93%) with a
maintenance dose of 5 mg/kg; 11 (47%) with a maintenance dose of
7.5 mg/kg and 1 (7%) with a maintenance dose of 10 mg/kg.
These data indicate that subjects with a low level of phenytoin
at 2 h are likely to require a higher maintenance dose to achieve a
level within the therapeutic reference range. None of those who
achieved sub-therapeutic levels at 2 h achieved supra-therapeutic
levels at 12 h and therefore the risk of using a higher initial
maintenance dose is low according to this simulated trial.
4. Discussion
The management of convulsive status epilepticus in children in
the UK changed in 2012 with the increase in the loading dose of
intravenous phenytoin from 18 to 20 mg/kg. Audits were
undertaken to evaluate the blood levels of phenytoin before and
after this increase [4,15]. These data were limited by the sample
size available, but overall little difference in the serum concentra-
tions within the therapeutic range achieved by the 18 and 20 mg/
kg infusions were noted (77% vs. 79%, respectively). We have now
utilised physiologically based pharmacokinetic simulation soft-
ware to assess the different loading doses of intravenous
phenytoin.
Although the dearth of phenytoin pharmacokinetic data in
children limits extensive validation of the model, the limited data
available suggests that the model is appropriate.
There were, predictably, a greater number of data points below
the 10 mg/mL level in the 18 mg/kg dose compared to 20 mg/kg.
Again predictably, there were more data points above 20 mg/mL at
the 20 mg/kg dose. This increase was quantiﬁable using the model,
with the 20 mg/kg dose increasing the mean C2h by 1.9 mg/mL and
AUC by 17 mg/mL/h. This increase in AUC may predispose to more
adverse effects, although we note this is not supported by the only
current study in this area [4]. Overall, the inter-individual variation
in the phenytoin level achieved using either 18 or 20 mg/kg is
greater than the increase noted with the increased dose.
Table 1
Frequency of individuals with a Cmax value within or outside the range 10–20 mg/mL following a maintenance dose of either 2.5, 5 or 7.5 mg/kg.
Maintenance dose
administered
The percentage of populations simulated Cmax values following an intravenous maintenance dose 12 h following the loading dose
18 mg/kg 20 mg/kg
<10 mg/mL 10–20 mg/mL >20 mg/mL <10 mg/mL 10–20 mg/mL >20 mg/mL
2.5 mg/kg 31 63 6 27 63 10
5.0 mg/kg 20 66 14 16 62 22
7.5 mg/kg 11 59 30 7 58 35
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differences, but do serve as a reminder to clinicians that the change
in the loading dose of phenytoin may affect the clinical outcomes
in some patients. Previous work in adult patients [16] has
suggested that the minimum concentration of phenytoin in which
clinical improvement is seen is 10 mg/mL. The reduction in the
proportion of the population with sub-therapeutic concentrations
(<10 mg/mL) from 22% to 15% achieved by increasing from 18 to
20 mg/kg is therefore a potential beneﬁt, decreasing the likelihood
of unsuccessful treatment of status epilepticus. Conversely, the
higher proportion of children with levels greater than 20 and
30 mg/mL with the 20 mg/kg dose increases the risk of clinically
signiﬁcant toxicity, although we do note that there were very low
rates of adverse effects in the 20 mg/kg population of patients
previously studied [4].
This work has also provided some insight into common clinical
dilemmas that follow the use of a phenytoin infusion for the
treatment of convulsive status epilepticus. The ﬁrst of these is the
timing and dose of maintenance therapy with phenytoin, should
this be required. The current recommendation in the British
National Formulary for Children (BNFc) for intravenous phenytoin
maintenance doses are (for children up to 12 years) 2.5–5 mg/kg
BD [17]. This has not been amended to take into account the
increase in the recommended loading dose of phenytoin from 18 to
20 mg/kg [18]. The modelling data have indicated that the BNFc
recommendation remains appropriate in that the commencement
of maintenance dosing 12 h following the loading dose and using
both the 2.5 mg and 5 mg/kg doses, will maintain most children in
the therapeutic reference range. However, the authors would
recommend therapeutic drug monitoring in view of the narrow
therapeutic index for phenytoin and the wide inter-individual
variation in the pharmacokinetics of the drug.
The second most common clinical dilemma is to determine how
best to increase the serum concentration in a child who has a sub-
therapeutic phenytoin concentration (<10 mg/mL) following the
initial loading dose. The model suggests that, assuming seizure
control has been achieved, for a population with a blood level of
less than 10 mg/mL, an increase in the ﬁrst intravenous mainte-
nance dose of 5–10 mg/kg is likely to raise the blood level to within
the therapeutic reference range. A limitation of the modelling with
respect to this analysis is that the low serum concentration may be
attributable to patient factors (including concomitant medica-
tions), and that population-modelling may not necessarily
accurately represent the change for an individual patient. We
have also not been able to take account of confounders such as
other anti-epileptic medication, or possible changes with age.
Nevertheless, we consider that these data provide a starting point
for future research, particularly in view of the fact there have been
no previous attempts to model these data in children.
The use of modelling populations also has more generic
limitations. We acknowledge that these data will not necessarily
inform clinical practice for an individual patient. We also
acknowledge that although the model fairly accurately predicted
the mean C2h for each dose, the number of sub-therapeutic levelsfor 20 mg/kg was different to that observed in clinical work
published previously [4]. However, there have been many
successful uses of modelling in paediatrics [12,13], that have
helped guide safe and effective prescribing practice. Clinicians
need to be aware of the possibility of that a loading dose of 20 mg/
kg may cause high (supra-therapeutic) blood levels and therefore
has the potential for greater toxicity (although only low rates have
been reported to date). These data provide reassurance that both
the currently recommended BNFc IV loading dose for phenytoin
(20 mg/kg), as well as the IV maintenance dose recommendations,
are appropriate.
5. Conclusions
Use of PBPK modelling suggests that children receiving the
20 mg/kg intravenous loading dose are at slightly increased risk of
supra-therapeutic blood levels. Therapeutic drug monitoring is
required to monitor serum concentrations, and the dose regime
suggested by the BNFc appears appropriate.
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